Basilea to Continue Late-Stage Antifungal Study

Swiss biotechnology group Basilea said it would resume recruitment of patients into a late-stage trial of an antifungal treatment in the first half of 2010 after a U.S. safety panel recommended the study’s continuation.
The Post Chronicle